The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin) within 14 days of an acute myocardial infarction (AMI) reduced the risk of a ...
Jardiance is also authorised to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. According to the FDA, heart disease impacts more than ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback